The Rising tide of PBM Reform: State Battles & the Push for Federal Action
Pharmacy Benefit Managers (pbms) are facing increasing scrutiny,sparking a wave of legal challenges and legislative efforts aimed at increasing transparency and controlling drug costs. A recent Arkansas law attempting to regulate PBM corporate structure has been temporarily blocked,but the broader movement for PBM reform is gaining momentum across the nation.This article dives into the current landscape,exploring the legal battles,proposed federal legislation,and the critical need for a unified approach.
Arkansas Law & the Commerce Clause Debate
A recent Arkansas law designed to regulate pbms has been halted by a federal judge, raising questions about its constitutionality under the Commerce Clause.The core of the dispute centers on whether the law unduly burdens interstate commerce.
Matthew Seiler, General Counsel at the National Community Pharmacists Association (NCPA), believes the decision was incorrect. He argues the law focuses on PBM structure, not regulation of out-of-state entities. “Reasonable minds will agree that this does not violate the Commerce Clause,” Seiler stated.
This case highlights a key challenge: states attempting to regulate PBMs frequently enough face legal pushback centered on federal authority over interstate commerce.
Why National Reform is Crucial
While states are stepping up, experts agree a national solution is essential. A patchwork of state regulations creates complexity and may not deliver the comprehensive changes needed to truly address PBM practices.
“Meaningful PBM reform needs to come from a national level instead of a patchwork of states,” explains policy expert Caroline Deacon. The current focus in Congress offers a promising path forward.
Key Federal Legislation on the Table
Several bills are currently being considered in Congress, targeting various aspects of PBM operations. Here’s a breakdown of the most important proposals:
The Patients Deserve Price Tags Act: This bipartisan bill aims to increase transparency across the healthcare system.It would require providers to publish service costs, giving you the ability to compare prices and access crucial claims data.
The PBM Reform Act: This legislation tackles specific PBM practices.It would ban spread pricing in Medicaid (where PBMs profit from the difference between what they charge payers and what they reimburse pharmacies) and delink PBM compensation from drug costs under Medicare Part D.
The Patients Before Monopolies Act: This more ambitious bill seeks to ban the joint ownership of PBMs and pharmacies. While potentially a “bridge too far” currently, it signals a desire for more fundamental change.
State-Level Action Continues
In the absence of swift federal action, states are forging ahead with their own regulations. California recently proposed a bill to delink PBM compensation from list prices, mirroring efforts at the federal level.Though, some argue that focusing solely on PBMs misses the mark. paul Markovich, CEO of Ascendiun (the parent company of Blue shield of California), contends that PBMs don’t directly control drug prices. He uses the analogy of Amazon – the box doesn’t dictate the contents’ cost.
The Risk of Losing Momentum
Deacon warns against complacency. She fears that state-level successes could discourage Congress from pursuing federal reform.
“What I would hate to see is Congress lose their energy and impetus… That would be a real lost opportunity,” she said. Most states, she believes, would prefer a federal solution to address the systemic issues with PBMs.
Why the Focus on pbms?
The increasing scrutiny of PBMs isn’t arbitrary. states are responding to a growing problem. They aren’t proactively seeking to regulate PBMs,but rather reacting to the impact these companies have on healthcare costs and access.
The fight for PBM reform is far from over. The Arkansas case, coupled with the flurry of legislative activity, demonstrates a growing recognition of the need for change. Whether that change comes from state capitals or Washington, D.C., remains to be seen. But one thing is clear: the pressure on PBMs is intensifying, and the demand for transparency and affordability in prescription drug pricing is only growing louder.
Image: Rawf8, Getty Images
Disclaimer: I am an AI chatbot and cannot provide legal or financial advice. This article is for informational purposes only.*
Related reading